2 articles in this category
High debt/equity and negative FCF clash with weak chemical pricing, triggering earnings downgrade; stock likely to drift lower near-term.
Strong free cash flow and low valuation multiples meet recent price momentum, suggesting near-term upside despite margin pressures.